Global Anti-Venom Industry Research Report, Growth Trends and Competitive Analysis 2021-2027

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.

In 2020, the global Anti-Venom market size was US$ 959.2 million and is forecast to 1227.8 million US in 2027, growing at a CAGR of 4.2% during the 2021-2027. In this study, 2020 has been considered as the base year and 2021 to 2027 as the forecast period to estimate the market size for Anti-Venom.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Anti-Venom market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Anti-Venom market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Anti-Venom market. Readers of the report can become informed about current and future trends of the global Anti-Venom market and how they will impact market growth during the forecast period.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom

Segment by Application
Non-profit Institutions
Hospitals and Clinic

By Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm